The 50-day moving average for INMD moved above the 200-day moving average on December 17, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The RSI Indicator entered the oversold zone -- be on the watch for INMD's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INMD advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 228 cases where INMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on December 05, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on INMD as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for INMD turned negative on December 05, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
INMD moved below its 50-day moving average on December 16, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INMD crossed bearishly below the 50-day moving average on December 19, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.247) is normal, around the industry mean (23.300). P/E Ratio (9.130) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (43.338).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
a developer of minimally-invasive aesthetic medical products
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, INMD has been loosely correlated with CERS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INMD jumps, then CERS could also see price increases.
Ticker / NAME | Correlation To INMD | 1D Price Change % | ||
---|---|---|---|---|
INMD | 100% | -0.64% | ||
CERS - INMD | 40% Loosely correlated | N/A | ||
BNGO - INMD | 38% Loosely correlated | -2.74% | ||
MASS - INMD | 37% Loosely correlated | +6.19% | ||
TWST - INMD | 37% Loosely correlated | +9.90% | ||
CRL - INMD | 37% Loosely correlated | +1.99% | ||
More |